PRODUCT DETAILS VIEW ALL PRODUCTS

Allercet M Syrup(Montelukast + Levocetirizine)

  • Each 5 ml of syrup contains: Montelukast 4 mg and Levocetirizine hydrochloride IP 2.5 mg.
  • Indicated for treatment of allergic rhinitis
  • Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit bronchoconstriction due to inhaled LTD4 in asthmatics. Levocetirizine, the R-enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors.
  • Children (2-5 years): 5 ml syrup once daily.
  • Contraindicated in patients with known hypersensitivity to montelukast, levocetirizine, to other piperazine derivatives or to any of the excipients. In patients with end stage renal disease at less than 10 ml/min creatinine clearance, and patients undergoing haemodialysis. Children 6 months to 11 years of age with impaired renal function should not be administered.
  • Neuropsychiatric events have been reported in patients taking montelukast. Monitor closely and instruct patients to be alert for neuropsychiatric events. While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, montelukast should not be abruptly substituted for inhaled or oral corticosteroids.
  • Allercet-M may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma.
  • Dyspepsia, abdominal pain, rash, dizziness, headache, fatigue, fever, trauma, cough, nasal congestion, somnolence, fatigue, dry mouth.
  • Anti-Allergics